PRGO Quote, Financials, Valuation and Earnings

Amarin Corp. Plc has a net margin of 1.22% compared to Perrigo Co. Plc's net margin of -15.58%. Perrigo Co. Plc's return on equity of -0.66% beat Amarin Corp. Plc's return on equity of -17.79%.

Perrigo Co. Plc has a consensus price target of $21.00, signalling upside risk potential of 52.73%. On the other hand Amarin Corp. Plc has an analysts' consensus of $12.00 which suggests that it could fall by -12.41%. Given that Perrigo Co. Plc has higher upside potential than Amarin Corp. Plc, analysts believe Perrigo Co. Plc is more attractive than Amarin Corp. Plc.

Perrigo Co. Plc has a beta of 0.386, which suggesting that the stock is 61.422% less volatile than S&P 500. In comparison Amarin Corp. Plc has a beta of 0.708, suggesting its less volatile than the S&P 500 by 29.246%.

Perrigo Co. Plc has a quarterly dividend of $0.29 per share corresponding to a yield of 8.44%. Amarin Corp. Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Perrigo Co. Plc pays 94.9% of its earnings as a dividend. Amarin Corp. Plc pays out -- of its earnings as a dividend. Perrigo Co. Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Perrigo Co. Plc quarterly revenues are $1B, which are larger than Amarin Corp. Plc quarterly revenues of $49.4M. Perrigo Co. Plc's net income of $12.7M is higher than Amarin Corp. Plc's net income of -$7.7M. Notably, Perrigo Co. Plc's price-to-earnings ratio is -- while Amarin Corp. Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Perrigo Co. Plc is 0.44x versus 7.15x for Amarin Corp. Plc. Usually stocks with elevated PS ratios are considered overvalued.

Jazz Pharmaceuticals Plc has a net margin of 1.22% compared to Perrigo Co. Plc's net margin of 22.33%. Perrigo Co. Plc's return on equity of -0.66% beat Jazz Pharmaceuticals Plc's return on equity of -9.16%.

Perrigo Co. Plc has a consensus price target of $21.00, signalling upside risk potential of 52.73%. On the other hand Jazz Pharmaceuticals Plc has an analysts' consensus of $213.00 which suggests that it could grow by 24.71%. Given that Perrigo Co. Plc has higher upside potential than Jazz Pharmaceuticals Plc, analysts believe Perrigo Co. Plc is more attractive than Jazz Pharmaceuticals Plc.

Perrigo Co. Plc has a beta of 0.386, which suggesting that the stock is 61.422% less volatile than S&P 500. In comparison Jazz Pharmaceuticals Plc has a beta of 0.305, suggesting its less volatile than the S&P 500 by 69.522%.

Perrigo Co. Plc has a quarterly dividend of $0.29 per share corresponding to a yield of 8.44%. Jazz Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Perrigo Co. Plc pays 94.9% of its earnings as a dividend. Jazz Pharmaceuticals Plc pays out -- of its earnings as a dividend. Perrigo Co. Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Perrigo Co. Plc quarterly revenues are $1B, which are smaller than Jazz Pharmaceuticals Plc quarterly revenues of $1.1B. Perrigo Co. Plc's net income of $12.7M is lower than Jazz Pharmaceuticals Plc's net income of $251.4M. Notably, Perrigo Co. Plc's price-to-earnings ratio is -- while Jazz Pharmaceuticals Plc's PE ratio is 15.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Perrigo Co. Plc is 0.44x versus 2.51x for Jazz Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.

Medtronic Plc has a net margin of 1.22% compared to Perrigo Co. Plc's net margin of 15.42%. Perrigo Co. Plc's return on equity of -0.66% beat Medtronic Plc's return on equity of 9.84%.

Perrigo Co. Plc has a consensus price target of $21.00, signalling upside risk potential of 52.73%. On the other hand Medtronic Plc has an analysts' consensus of $110.97 which suggests that it could grow by 14.08%. Given that Perrigo Co. Plc has higher upside potential than Medtronic Plc, analysts believe Perrigo Co. Plc is more attractive than Medtronic Plc.

Perrigo Co. Plc has a beta of 0.386, which suggesting that the stock is 61.422% less volatile than S&P 500. In comparison Medtronic Plc has a beta of 0.710, suggesting its less volatile than the S&P 500 by 28.968%.

Perrigo Co. Plc has a quarterly dividend of $0.29 per share corresponding to a yield of 8.44%. Medtronic Plc offers a yield of 2.9% to investors and pays a quarterly dividend of $0.71 per share. Perrigo Co. Plc pays 94.9% of its earnings as a dividend. Medtronic Plc pays out 77.47% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Perrigo Co. Plc quarterly revenues are $1B, which are smaller than Medtronic Plc quarterly revenues of $9B. Perrigo Co. Plc's net income of $12.7M is lower than Medtronic Plc's net income of $1.4B. Notably, Perrigo Co. Plc's price-to-earnings ratio is -- while Medtronic Plc's PE ratio is 26.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Perrigo Co. Plc is 0.44x versus 3.60x for Medtronic Plc. Usually stocks with elevated PS ratios are considered overvalued.

Skye Bioscience, Inc. has a net margin of 1.22% compared to Perrigo Co. Plc's net margin of --. Perrigo Co. Plc's return on equity of -0.66% beat Skye Bioscience, Inc.'s return on equity of -91.57%.

Perrigo Co. Plc has a consensus price target of $21.00, signalling upside risk potential of 52.73%. On the other hand Skye Bioscience, Inc. has an analysts' consensus of $8.25 which suggests that it could grow by 888.73%. Given that Skye Bioscience, Inc. has higher upside potential than Perrigo Co. Plc, analysts believe Skye Bioscience, Inc. is more attractive than Perrigo Co. Plc.

Perrigo Co. Plc has a beta of 0.386, which suggesting that the stock is 61.422% less volatile than S&P 500. In comparison Skye Bioscience, Inc. has a beta of 2.676, suggesting its more volatile than the S&P 500 by 167.642%.

Perrigo Co. Plc has a quarterly dividend of $0.29 per share corresponding to a yield of 8.44%. Skye Bioscience, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Perrigo Co. Plc pays 94.9% of its earnings as a dividend. Skye Bioscience, Inc. pays out -- of its earnings as a dividend. Perrigo Co. Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Perrigo Co. Plc quarterly revenues are $1B, which are larger than Skye Bioscience, Inc. quarterly revenues of --. Perrigo Co. Plc's net income of $12.7M is higher than Skye Bioscience, Inc.'s net income of -$12.8M. Notably, Perrigo Co. Plc's price-to-earnings ratio is -- while Skye Bioscience, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Perrigo Co. Plc is 0.44x versus 476.49x for Skye Bioscience, Inc.. Usually stocks with elevated PS ratios are considered overvalued.